Zenshine Pharmaceuticals (Nanjing) Group Co., Ltd.

征祥医药（南京）集团股份有限公司

Commercial-stage biopharmaceutical company developing small-molecule therapeutics for viral infectious diseases, oncology, and inflammatory disorders in China. Its core product, sebaloxavir marboxil, an influenza PA endonuclease inhibitor, was approved by the NMPA in 2025 for treating influenza in adults and adolescents.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Social insurance & housing fund
• Customer concentration
• Supplier concentration
• Overlapping customers and suppliers
• Connected or related major customers / suppliers
• Distribution model
• Reliance on platforms, partners or licences
• Single product, business line or region
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Key long-term agreements
• Seasonality and cyclicality
• Losses and path to profitability
• Negative operating cash flow
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Preferred shares and fair-value liabilities
• Investments and fair-value assets
• Chapter 18A biotech